LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diagnostic Biomarker Predicts Risk of Opisthorchiasis Cholangiocarcinoma

By LabMedica International staff writers
Posted on 10 Mar 2022
Image: Opisthorchiasis-associated cholangiocarcinoma. (A) Cholangiocarcinoma specimen showing adult worms in the bile duct (blue arrows). (B) Adult Opisthorchis viverrini recovered from the liver (Photo courtesy of Khon Kaen University)
Image: Opisthorchiasis-associated cholangiocarcinoma. (A) Cholangiocarcinoma specimen showing adult worms in the bile duct (blue arrows). (B) Adult Opisthorchis viverrini recovered from the liver (Photo courtesy of Khon Kaen University)

Opisthorchiasis is caused by an infection with fish-borne liver flukes of the genus Opisthorchis. Opisthorchiasis frequently leads to chronic inflammation in the biliary tract and is classified as a group 1 biological carcinogen by the International Agency for Research on Cancer as a definitive risk for cholangiocarcinoma (CCA).

Opisthorchiasis infection is considered heavy when there are 10,000-30,000 eggs in one gram of feces. Symptoms of heavier infections with Opisthorchis viverrini may include: diarrhea, epigastric and upper right quadrant pain, lack of appetite (anorexia), fatigue, yellowing of the eyes and skin (jaundice) and mild fever.

Parasitologists at the Khon Kaen University (Khon Kaen, Thailand) included in a study 103 serum samples. These sera were assigned to three groups as follows: group I, CCA group (n = 36); group II, other cancers and liver cirrhosis group (n = 47) including hepatocellular carcinoma (n = 28), liver cirrhosis (n = 4), colorectal cancer (n = 8), and brain cancer (n = 7); and group III, other healthy individuals (n = 20). The scientists used the rapid immunochromatographic test (ICT) to detect anti-Opisthorchis viverrini IgG and IgG4 subclass antibodies in sera of patients with CCA. The ICT kits were developed based on soluble antigens excreted and secreted by O. viverrini adult worms.

The investigators reported that ICT indicated sera was positive for IgG and IgG4 antibodies, respectively, in 22 (61.1%) and 15 (41.6%) participants of the 36 study participants diagnosed with CCA. The study also included groups with other cancers and with liver cirrhosis, where the IgG ICT and IgG4 ICT kits were 27.7% (13/47) and 25.5% (12/47) positive, respectively. Neither total the IgG ICT nor the IgG4 ICT yielded positive results in a control group of 20 healthy participants. Moreover, the percentage positivity rate using the ICT for total IgG between the CCA group and the other cancers and liver cirrhosis group was significantly different. By contrast, no significant difference between these groups was apparent in the ICT for IgG4 antibody. The CCA group was 6.53 times more likely to have positive anti–O. viverrini IgG antibody (odds ratio 6.53) and 3.27 times more likely to have positive anti–O. viverrini IgG4 antibody (odds ratio 3.27) than the non-CCA group.

The authors concluded that these findings highlighted the diagnostic potential of a rapid ICT platform that uses ES products from O. viverrini flukes for serodiagnosis of opisthorchiasis-associated CCA. The study was published on March 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
Khon Kaen University 

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more